ENSC
Price
$2.38
Change
+$0.04 (+1.71%)
Updated
Jun 6 closing price
Capitalization
5.51M
YMAB
Price
$5.27
Change
+$0.17 (+3.33%)
Updated
Jun 6 closing price
Capitalization
238.71M
61 days until earnings call
Interact to see
Advertisement

ENSC vs YMAB

Header iconENSC vs YMAB Comparison
Open Charts ENSC vs YMABBanner chart's image
Ensysce Biosciences
Price$2.38
Change+$0.04 (+1.71%)
Volume$80.84K
Capitalization5.51M
Y-mAbs Therapeutics
Price$5.27
Change+$0.17 (+3.33%)
Volume$110.17K
Capitalization238.71M
ENSC vs YMAB Comparison Chart
Loading...
ENSC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENSC vs. YMAB commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENSC is a Buy and YMAB is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (ENSC: $2.38 vs. YMAB: $5.27)
Brand notoriety: ENSC and YMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENSC: 3% vs. YMAB: 48%
Market capitalization -- ENSC: $5.51M vs. YMAB: $238.71M
ENSC [@Biotechnology] is valued at $5.51M. YMAB’s [@Biotechnology] market capitalization is $238.71M. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENSC’s FA Score shows that 1 FA rating(s) are green whileYMAB’s FA Score has 0 green FA rating(s).

  • ENSC’s FA Score: 1 green, 4 red.
  • YMAB’s FA Score: 0 green, 5 red.
According to our system of comparison, ENSC is a better buy in the long-term than YMAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENSC’s TA Score shows that 5 TA indicator(s) are bullish while YMAB’s TA Score has 5 bullish TA indicator(s).

  • ENSC’s TA Score: 5 bullish, 1 bearish.
  • YMAB’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ENSC is a better buy in the short-term than YMAB.

Price Growth

ENSC (@Biotechnology) experienced а +7.21% price change this week, while YMAB (@Biotechnology) price change was +14.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

ENSC is expected to report earnings on Mar 10, 2025.

YMAB is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
YMAB($239M) has a higher market cap than ENSC($5.51M). YMAB YTD gains are higher at: -32.695 vs. ENSC (-70.762). ENSC has higher annual earnings (EBITDA): -6.7M vs. YMAB (-30.67M). YMAB has more cash in the bank: 67.2M vs. ENSC (3.5M). ENSC has less debt than YMAB: ENSC (302K) vs YMAB (820K). YMAB has higher revenues than ENSC: YMAB (87.7M) vs ENSC (0).
ENSCYMABENSC / YMAB
Capitalization5.51M239M2%
EBITDA-6.7M-30.67M22%
Gain YTD-70.762-32.695216%
P/E Ratio0.02N/A-
Revenue087.7M-
Total Cash3.5M67.2M5%
Total Debt302K820K37%
FUNDAMENTALS RATINGS
ENSC vs YMAB: Fundamental Ratings
ENSC
YMAB
OUTLOOK RATING
1..100
2926
VALUATION
overvalued / fair valued / undervalued
1..100
28
Undervalued
36
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9994
PRICE GROWTH RATING
1..100
6559
P/E GROWTH RATING
1..100
63100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ENSC's Valuation (28) in the null industry is in the same range as YMAB (36) in the Pharmaceuticals Major industry. This means that ENSC’s stock grew similarly to YMAB’s over the last 12 months.

ENSC's Profit vs Risk Rating (100) in the null industry is in the same range as YMAB (100) in the Pharmaceuticals Major industry. This means that ENSC’s stock grew similarly to YMAB’s over the last 12 months.

YMAB's SMR Rating (94) in the Pharmaceuticals Major industry is in the same range as ENSC (99) in the null industry. This means that YMAB’s stock grew similarly to ENSC’s over the last 12 months.

YMAB's Price Growth Rating (59) in the Pharmaceuticals Major industry is in the same range as ENSC (65) in the null industry. This means that YMAB’s stock grew similarly to ENSC’s over the last 12 months.

ENSC's P/E Growth Rating (63) in the null industry is somewhat better than the same rating for YMAB (100) in the Pharmaceuticals Major industry. This means that ENSC’s stock grew somewhat faster than YMAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENSCYMAB
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
80%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
88%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 1 day ago
81%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
N/A
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ENSC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MACCX16.450.15
+0.92%
MoA Catholic Values Index Fund Class
CSXCX46.28N/A
N/A
Calvert US Large Cap Core Rspnb Idx C
FIICX17.04N/A
N/A
Fidelity Advisor Mid Cap II C
VYMVX17.49N/A
N/A
Voya Mid Cap Research Enhanced Index R
RPMFX15.27N/A
N/A
Reinhart Genesis PMV Advisor

ENSC and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENSC has been loosely correlated with MLLCF. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ENSC jumps, then MLLCF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENSC
1D Price
Change %
ENSC100%
+1.71%
MLLCF - ENSC
37%
Loosely correlated
N/A
HNSBF - ENSC
33%
Loosely correlated
N/A
SYRE - ENSC
31%
Poorly correlated
+2.11%
NEUP - ENSC
31%
Poorly correlated
-3.92%
YMAB - ENSC
30%
Poorly correlated
+3.33%
More

YMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, YMAB has been loosely correlated with ARWR. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if YMAB jumps, then ARWR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To YMAB
1D Price
Change %
YMAB100%
+3.33%
ARWR - YMAB
52%
Loosely correlated
+2.13%
CRSP - YMAB
50%
Loosely correlated
+8.53%
FATE - YMAB
48%
Loosely correlated
+19.40%
OCUL - YMAB
48%
Loosely correlated
+6.62%
IMNM - YMAB
47%
Loosely correlated
+0.11%
More